“Just give it to me straight — does HRT give you breast cancer or not?”

"Does HRT cause breast cancer?" is a risk-communication station where the mark lies in translating evidence into meaningful numbers and supporting an informed choice, not in a yes/no. Answer honestly: there is an increased risk of breast cancer with combined (oestrogen + progestogen) HRT that rises with duration and falls after stopping but persists in part for more than 10 years (MHRA Drug Safety Update, August 2019), while oestrogen-only HRT (for women without a uterus) carries the smallest increase (about 10 extra per 1000 over 20 years for 5 years from 50 — NICE NG23 discussion aid, 2024) — avoiding both false reassurance and the headline’s scaremongering. The core skill is to express risk in absolute terms and natural frequencies ("of 1000 women starting around 50 who never use HRT, about 59 develop breast cancer over 20 years; five years of combined HRT adds about 20 extra cases, ten years about 33" — NICE NG23 discussion aid, 2024) rather than relative percentages, which make the change sound far larger, and to contextualise it with a sourced comparison — British Menopause Society Fast Facts (2025): the excess risk with 5 years of combined HRT at 50–59 is similar in size to that linked with obesity — not to dismiss it but to let her weigh it realistically and act on modifiable factors (weight, alcohol, activity). Be specific that type (oestrogen-only vs sequential vs continuous combined; any lower breast risk with micronised progesterone is uncertain, as MHRA 2019 found increased risk with any progestogen), duration and — for VTE rather than breast — route matter, and that the regimen can be tailored to minimise risk. Reconnect to her: the real benefit (symptom relief that "gave her life back", bone protection) and her individual risk profile, framing a values-based, revisitable decision, reviewed at least once a year, in which she weighs the benefit she actually feels against the honest absolute numbers. Validate the question, reassure she is not "asking for cancer", support her autonomy with clarity, offer written decision support and review, and remind her to report unscheduled bleeding. NICE NG12 (Suspected cancer: recognition and referral, last updated April 2026) is not the subject, though the bleeding safety-net still applies.